Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th International Conference on Children's Bone Health being held in Montreal from June 27-30. The data include an oral presentation of Week 104 data showing improvements in lower-extremity alignment from the recently completed pivotal ApproaCH Trial of TransCon® CNP (navepegritide) by Leanne Ward, M.D., Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa (Canada), as well as a late-breaking poster of radiographic and anthropometric data from Week 52 of the COACH Trial of combination therapy with TransCon CNP and TransCon hGH (lonapegsomatropin).

"These follow-up data reinforce the unique benefits of TransCon CNP alone and in combination with TransCon hGH in children with achondroplasia across areas of high unmet need identified by the achondroplasia community, including short limbs, narrow spinal canal dimensions, and lower extremity misalignment, which can lead to complications requiring highly invasive procedures in some individuals," said Aimee Shu, M.D., Executive Vice President, Chief Medical Officer at Ascendis Pharma. "We look forward to sharing more data from our monotherapy and combination therapy programs as they become available."

Ascendis data presentations at ICCBH 2026 include:

TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle. TransCon hGH is a prodrug of somatropin administered once weekly, providing sustained release of active, unmodified somatropin. TransCon CNP was approved under the trade name YUVIWEL® by the U.S. Food & Drug Administration (FDA) in February 2026 and is under review by the European Medicines Agency as a monotherapy for children with achondroplasia. TransCon hGH is approved by the FDA, European Commission, and other regulatory agencies and marketed as SKYTROFA® for the treatment of pediatric and adult growth hormone deficiency (in U.S.); it is investigational in achondroplasia and other indications.